The use of diabetes and weight-loss medications like Ozempic or Wegovy—called GLP-1 drugs—has exploded in recent years, with ...

A large-scale clinical trial found that intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) analog ...

Patients who would benefit from a GLP-1 face significant challenges when it comes to access. Shortages have made it difficult ...

GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

A new study supports the notion that the same mechanisms that help folks lose weight with Ozempic and its kin also work to ...

By Dr. Chinta Sidharthan A long-term study suggests GLP-1 agonists, especially semaglutide, may lower the risk of alcohol use ...

The two drugs are metformin, one of the most widely used diabetes medications, and the GLP-1 class of medications that ...

Mohammad Ali Sheffeh, MD, from the Mayo Clinic in Rochester, Minnesota, and colleagues examined the efficacy of GLP-1 RA or SGLT-2i initiation for reducing mortality or cardiovascular events among ...

11月17日，诺和诺德宣布其用于长期体重管理的胰高糖素样肽-1受体激动剂（GLP-1RA）周制剂司美格鲁肽（商品名：诺和盈）正式在中国上市，为中国超重和肥胖症患者提供减重选择。

HERSHEY, PA. — GLP-1 weight-loss drugs are having a “mild impact” on The Hershey Co.’s business, president and chief ...

华东医药另一个获批临床试验的产品DR10624注射液为道尔生物自主研发的一款长效三靶点激动剂，适应症为代谢相关脂肪性肝病/代谢相关脂肪性肝炎。截至目前全球尚无同时靶向FGF21R、GLP-1R和GCGR的长效三靶点激动剂药物上市，DR10624注射液具有“first-in-class”潜力。

作者：周绘出品：洞察IPO上交所ShangHai&深交所ShenZhen 新 股 上 ...